{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:48:42Z","timestamp":1793821722968,"version":"4.6.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Migraine is a leading cause of disability, estimated to affect one-in-ten people in Spain. This study aimed to describe the management of migraine in Spain and identify improvement areas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Non-interventional, retrospective, cross-sectional cohort study conducted using an electronic medical records database covering visits to public healthcare providers for 3% of the Spanish population. Patients with a migraine diagnosis (ICD-9 346) between 01\/2015 and 04\/2022 were included, as well as their demographic and clinical characteristics, prescribed migraine treatments and the specialty of the prescribing physicians.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The database included 61,204 patients diagnosed with migraine. A migraine treatment had been prescribed to 50.6% of patients over the last 24 months (only acute to 69.5%, both acute and preventive to 24.2%, and only preventive to 6.3%). The most frequently prescribed treatments were NSAIDs (56.3%), triptans (44.1%) and analgesics (28.9%). Antidepressants were the most common preventive treatment (prescribed to 17.9% of all treated patients and 58.7% of those treated with a preventive medication), and anti-CGRP monoclonal antibodies the least prescribed (1.7%; 5.7%). In 13.4% of cases, preventive medications were the first treatment: alone in 5.8% of cases and together with an acute medication in 7.6%. A fifth of patients who were initially prescribed with only acute treatment were later prescribed a preventive medication (20.7%). On average, it took 29.4 months for this change to occur. Two-thirds of patients started their preventive treatment in primary care (64.2%). The percentage of patients treated by a neurologist increased with the number of received preventive medications. However, 28.8% of patients who had already been prescribed five or more distinct preventive treatments were not treated by a neurologist. Migraine patients had between 1.2- and 2.2-times higher prevalence of comorbidities than the general population, age-gender adjusted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study emphasizes the need for improved management of migraine in Spain to reduce the risk of chronification and improve patient outcomes. More training and coordination across healthcare professionals is necessary to recognize and address risk factors for migraine progression, including multiple associated comorbidities and several lines of treatment, and to provide personalized treatment plans that address the complex nature of the condition.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-024-03600-8","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T06:01:38Z","timestamp":1712037698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Migraine treatment: quo vadis? Real-world data study (2015\u20132022) in Spain"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Carmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Armada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Moya-Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"issue":"1","key":"3600_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):1\u201317.","journal-title":"J Headache Pain"},{"key":"3600_CR2","doi-asserted-by":"crossref","unstructured":"Steiner T, Stovner L, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. In., vol. 21: BioMed Central; 2020: 1\u20134.","DOI":"10.1186\/s10194-020-01208-0"},{"key":"3600_CR3","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018, 38(1):1-211.","DOI":"10.1177\/0333102417738202"},{"issue":"7","key":"3600_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","volume":"35","author":"AM Adams","year":"2015","unstructured":"Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, Lipton RB. The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia. 2015;35(7):563\u201378.","journal-title":"Cephalalgia"},{"issue":"1","key":"3600_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","volume":"16","author":"Z Katsarava","year":"2012","unstructured":"Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86\u201392.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"3600_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe\u2013evidence from the Eurolight study. J Headache Pain. 2018;19(1):1\u20139.","journal-title":"J Headache Pain"},{"issue":"2","key":"3600_CR7","doi-asserted-by":"publisher","first-page":"e034926","DOI":"10.1136\/bmjopen-2019-034926","volume":"10","author":"J Darb\u00e0","year":"2020","unstructured":"Darb\u00e0 J, Mars\u00e0 A. Analysis of the management and costs of headache disorders in Spain during the period 2011\u20132016: a retrospective multicentre observational study. BMJ Open. 2020;10(2):e034926.","journal-title":"BMJ Open"},{"issue":"5","key":"3600_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z, Lainez J, Lampl C, Lant\u00e9ri-Minet M, Rastenyte D. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703\u201311.","journal-title":"Eur J Neurol"},{"issue":"12","key":"3600_CR9","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1111\/ene.14431","volume":"27","author":"P Irimia","year":"2020","unstructured":"Irimia P, Garrido-Cumbrera M, Santos\u2010Lasaosa S, Bra\u00e7e O, Colomina I, Blanch C, Pozo\u2010Rosich P. Estimating the savings associated with a migraine\u2010free life: results from the Spanish Atlas. Eur J Neurol. 2020;27(12):2616\u201324.","journal-title":"Eur J Neurol"},{"issue":"12","key":"3600_CR10","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1016\/j.jval.2022.09.746","volume":"25","author":"J Fern\u00e1ndez-Ferro","year":"2022","unstructured":"Fern\u00e1ndez-Ferro J, Ord\u00e1s-Bandera C, Rejas J, Ferro-Rey B, G\u00f3mez-Lus S. EE504 the Economic Burden of Migraine in Spain: a nationwide cost-of-illness Approach from the Year 2020 European Health Survey in Spain. Value Health. 2022;25(12):S154\u20135.","journal-title":"Value Health"},{"issue":"8","key":"3600_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1212\/WNL.0b013e31820d8af2","volume":"76","author":"A Manack","year":"2011","unstructured":"Manack A, Buse D, Serrano D, Turkel C, Lipton R. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76(8):711\u20138.","journal-title":"Neurology"},{"issue":"12","key":"3600_CR12","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1007\/s00415-023-11880-2","volume":"270","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Buse DC, Nahas SJ, Tietjen GE, Martin VT, L\u00f6f E, Brevig T, Cady R, Diener H-C. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol. 2023;270(12):5692\u2013710.","journal-title":"J Neurol"},{"key":"3600_CR13","doi-asserted-by":"crossref","unstructured":"Berger AA, Winnick A, Carroll AH, Welschmeyer A, Li N, Colon M, Paladini A, Ram\u00edrez GF, Hasoon J, Cornett EM. Rimegepant for the treatment of migraine. Health Psychol Res 2022, 10(5).","DOI":"10.52965\/001c.38534"},{"issue":"1","key":"3600_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-016-2211-8","volume":"5","author":"F Antonaci","year":"2016","unstructured":"Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016;5(1):1\u201314.","journal-title":"Springerplus"},{"key":"3600_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3389\/fnins.2020.00222","volume":"14","author":"P Gazerani","year":"2020","unstructured":"Gazerani P, Cairns BE. Sex-specific pharmacotherapy for migraine: a narrative review. Front NeuroSci. 2020;14:222.","journal-title":"Front NeuroSci"},{"key":"3600_CR16","unstructured":"Santos S, Pozo-Rosich P. Headache clinical practice manual. Span Soc Neurol Madrid: Ed Luzon 2020, 5."},{"issue":"1","key":"3600_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s10194-021-01267-x","volume":"22","author":"R Belv\u00eds","year":"2021","unstructured":"Belv\u00eds R, Irimia P, Pozo-Rosich P, Gonz\u00e1lez-Oria C, Cano A, Viguera J, S\u00e1nchez B, Molina F, Beltr\u00e1n I, Oterino A, et al. MAB-MIG: registry of the Spanish neurological society of erenumab for migraine prevention. J Headache Pain. 2021;22(1):74.","journal-title":"J Headache Pain"},{"key":"3600_CR18","doi-asserted-by":"crossref","unstructured":"Ambrosini A, Estemalik E, Pascual J, Rettiganti M, Stroud C, Day K, Ford J. Changes in acute headache medication use and health care resource utilization: results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER). J Managed care Specialty Pharm 2022:1\u201312.","DOI":"10.18553\/jmcp.2022.21375"},{"issue":"4","key":"3600_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40265-018-0865-y","volume":"78","author":"JJY Ong","year":"2018","unstructured":"Ong JJY, Wei DY-T, Goadsby PJ. Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs. 2018;78(4):411\u201337.","journal-title":"Drugs"},{"issue":"2","key":"3600_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an oral calcitonin gene\u2013related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"3600_CR21","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/head.13115","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Munjal S, Buse DC, Bennett A, Fanning KM, Burstein R, Reed ML. Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention Study. Headache: J Head Face Pain. 2017;57(7):1026\u201340.","journal-title":"Headache: J Head Face Pain"},{"issue":"6","key":"3600_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2165\/00003495-199855060-00020","volume":"55","author":"CM Perry","year":"1998","unstructured":"Perry CM, Markham A. Sumatriptan. Drugs. 1998;55(6):889\u2013922.","journal-title":"Drugs"},{"key":"3600_CR23","doi-asserted-by":"crossref","unstructured":"Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Reviews 2012(2).","DOI":"10.1002\/14651858.CD008614.pub2"},{"issue":"1","key":"3600_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10072-011-0551-2","volume":"32","author":"P Cortelli","year":"2011","unstructured":"Cortelli P, Allais G, Tullo V, Benedetto C, Zava D, Omboni S, Bussone G. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. Neurol Sci. 2011;32(1):95\u20138.","journal-title":"Neurol Sci"},{"issue":"1","key":"3600_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1046\/j.1526-4610.2003.03006.x","volume":"43","author":"RM Gallagher","year":"2003","unstructured":"Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache: J Head Face Pain. 2003;43(1):36\u201343.","journal-title":"Headache: J Head Face Pain"},{"issue":"10","key":"3600_CR26","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/head.13642","volume":"59","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Hutchinson S, Ailani J, Reed ML, Fanning KM, Manack Adams A, Buse DC. Discontinuation of Acute prescription medication for migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59(10):1762\u201372.","journal-title":"Headache"},{"issue":"2","key":"3600_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/head.12198","volume":"54","author":"RE Wells","year":"2014","unstructured":"Wells RE, Markowitz SY, Baron EP, Hentz JG, Kalidas K, Mathew PG, Halker R, Dodick DW, Schwedt TJ. Identifying the factors underlying discontinuation of triptans. Headache. 2014;54(2):278\u201389.","journal-title":"Headache"},{"issue":"1","key":"3600_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-022-01448-2","volume":"23","author":"P Irimia","year":"2022","unstructured":"Irimia P, Garc\u00eda-Azor\u00edn D, N\u00fa\u00f1ez M, D\u00edaz-Cerezo S, de Polavieja PG, Panni T, Sicras-Navarro A, Sicras-Mainar A, Ciudad A. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study. J Headache Pain. 2022;23(1):78.","journal-title":"J Headache Pain"},{"issue":"4","key":"3600_CR29","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, Wilcox TK, Kawata AK, Lipton RB. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644\u201355.","journal-title":"Headache"},{"issue":"10","key":"3600_CR30","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1093\/brain\/aww236","volume":"139","author":"PJ Goadsby","year":"2016","unstructured":"Goadsby PJ. Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients. Brain. 2016;139(10):2571\u20137.","journal-title":"Brain"},{"issue":"10","key":"3600_CR31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S1474-4422(15)00198-2","volume":"14","author":"H-C Diener","year":"2015","unstructured":"Diener H-C, Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015;14(10):1010\u201322.","journal-title":"Lancet Neurol"},{"key":"3600_CR32","doi-asserted-by":"crossref","unstructured":"Pavelic AR, W\u00f6ber C, Riederer F, Zebenholzer K. Monoclonal antibodies against calcitonin gene-related peptide for Migraine Prophylaxis: a systematic review of real-World Data. Cells 2022, 12(1).","DOI":"10.3390\/cells12010143"},{"key":"3600_CR33","unstructured":"BIFIMED. [https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=723375]"},{"issue":"3","key":"3600_CR34","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/neurolint15030067","volume":"15","author":"H Ple\u0219","year":"2023","unstructured":"Ple\u0219 H, Florian I-A, Timis T-L, Covache-Busuioc R-A, Glavan L-A, Dumitrascu D-I, Popa AA, Bordeianu A, Ciurea AV. Migraine: advances in the Pathogenesis and treatment. Neurol Int. 2023;15(3):1052\u2013105.","journal-title":"Neurol Int"},{"key":"3600_CR35","unstructured":"Libro Blanco de. La Migra\u00f1a en Espa\u00f1a in.: Lilly."},{"issue":"4","key":"3600_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/0333102410382794","volume":"31","author":"J Mat\u00edas-Guiu","year":"2011","unstructured":"Mat\u00edas-Guiu J, Porta-Etessam J, Mateos V, D\u00edaz-Insa S, Lopez-Gil A, Fern\u00e1ndez C. One-year prevalence of migraine in Spain: a nationwide population-based survey. Cephalalgia. 2011;31(4):463\u201370.","journal-title":"Cephalalgia"},{"key":"3600_CR37","doi-asserted-by":"crossref","unstructured":"Salazar A, Berrocal L, Failde I. Prevalence of Migraine in General Spanish Population; factors related and use of Health resources. Int J Environ Res Public Health 2021, 18(21).","DOI":"10.3390\/ijerph182111145"},{"issue":"10","key":"3600_CR38","first-page":"577","volume":"55","author":"V Mateos","year":"2012","unstructured":"Mateos V, Porta-Etessam J, Armengol-Bertolin S, Larios C, Garcia M. [Initial situation and approach to the care of migraine in neurology services in Spain: the PRIMERA study]. Rev Neurol. 2012;55(10):577\u201384.","journal-title":"Rev Neurol"},{"issue":"2","key":"3600_CR39","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s40122-021-00331-3","volume":"10","author":"P Pozo-Rosich","year":"2021","unstructured":"Pozo-Rosich P, Lucas C, Watson DP, Gaul C, Ramsden E, Ritter S, Martelletti P, Snellman J. Burden of migraine in patients with preventive treatment failure attending European headache specialist centers: real-world evidence from the BECOME study. Pain Therapy. 2021;10(2):1691\u2013708.","journal-title":"Pain Therapy"},{"key":"3600_CR40","doi-asserted-by":"crossref","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, Pozo-Rosich P, Reuter U, de la Torre ER, Sanchez, Del Rio M et al. European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 2020, 21(1):76.","DOI":"10.1186\/s10194-020-01130-5"},{"issue":"1","key":"3600_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Ulud\u00fcz D, Versijpt J, Ducros A, Gil-Gouveia R, Katsarava Z, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022;23(1):133.","journal-title":"J Headache Pain"},{"key":"3600_CR42","unstructured":"Ayala AEG. Farmacoterapia De La migra\u00f1a. Tratamiento sintom\u00e1tico Y Preventivo OFFAR 2008, 27(2)."},{"issue":"01","key":"3600_CR43","doi-asserted-by":"publisher","first-page":"334","DOI":"10.31434\/rms.v5i1.334","volume":"5","author":"AR Castillo","year":"2020","unstructured":"Castillo AR, Zumbado MJB, V\u00edquez MJ. Migra\u00f1a: tratamiento de crisis y farmacoterapia profil\u00e1ctica. Revista M\u00e9dica Sinergia. 2020;5(01):334.","journal-title":"Revista M\u00e9dica Sinergia"},{"issue":"3","key":"3600_CR44","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s40744-021-00327-7","volume":"8","author":"F Castro-Dom\u00ednguez","year":"2021","unstructured":"Castro-Dom\u00ednguez F, Vargas-Negr\u00edn F, P\u00e9rez C, Guti\u00e9rrez-Prieto H, Rebollo P. Unmet needs in the osteoarthritis chronic moderate to severe pain management in Spain: a real word data study. Rheumatol Therapy. 2021;8(3):1113\u201327.","journal-title":"Rheumatol Therapy"},{"key":"3600_CR45","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Insa S, Navarro-Zornoza M, S\u00e1nchez-de la Rosa R, Guerrero AL. Characterisation of the management of patients with migraine in the primary care setting in Spain. Analysis of the results of the European My-LIFE anamnesis project. Neurolog\u00eda (English Ed) 2023.","DOI":"10.1016\/j.nrleng.2021.10.009"},{"issue":"10","key":"3600_CR46","doi-asserted-by":"publisher","first-page":"e037190","DOI":"10.1136\/bmjopen-2020-037190","volume":"10","author":"J Pascual","year":"2020","unstructured":"Pascual J, Pozo-Rosich P, Carrillo I, Rodr\u00edguez-Justo S, Jim\u00e9nez-Hern\u00e1ndez D, Layos-Romero A, Bail\u00f3n-Santamar\u00eda C, Torres A, Mart\u00ednez-Garc\u00eda A, Ignacio E. Proposal of a clinical care pathway for quality and safe management of headache patients: a consensus study report. BMJ open. 2020;10(10):e037190.","journal-title":"BMJ open"},{"issue":"4","key":"3600_CR47","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10194-011-0320-x","volume":"12","author":"TJ Steiner","year":"2011","unstructured":"Steiner TJ, Antonaci F, Jensen R, Lainez M, Lanteri-Minet M, Valade D. Recommendations for headache service organisation and delivery in Europe. J Headache Pain. 2011;12(4):419\u201326.","journal-title":"J Headache Pain"},{"issue":"1","key":"3600_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-0988-x","volume":"20","author":"T Dresler","year":"2019","unstructured":"Dresler T, Caratozzolo S, Guldolf K, Huhn J-I, Loiacono C, Niiberg-Pikks\u00f6\u00f6t T, Puma M, Sforza G, Tobia A, Ornello R. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J Headache Pain. 2019;20(1):1\u201317.","journal-title":"J Headache Pain"},{"issue":"1","key":"3600_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-87352-2","volume":"11","author":"P Irimia","year":"2021","unstructured":"Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, Aguirre-Vazquez M, Correa-Fern\u00e1ndez J, Colomina I, Pozo-Rosich P. Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas. Sci Rep. 2021;11(1):1\u20139.","journal-title":"Sci Rep"},{"key":"3600_CR50","unstructured":"Lipton RB, Martin VT, Reed ML, Fanning KM, Adams AM, Buse DC, Goadsby P. Migraine progression in natural subgroups of migraine based on comorbidities and concomitant conditions: results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. In: CEPHALALGIA: 2018: SAGE PUBLICATIONS LTD 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND; 2018: 7\u20139."},{"issue":"1","key":"3600_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-1084-y","volume":"21","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ, Munjal S, Singh P, Lipton RB. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2020;21(1):1\u201316.","journal-title":"J Headache Pain"},{"issue":"5","key":"3600_CR52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/0333102419883355","volume":"40","author":"J Xu","year":"2020","unstructured":"Xu J, Kong F, Buse DC. Predictors of episodic migraine transformation to chronic migraine: a systematic review and meta-analysis of observational cohort studies. Cephalalgia. 2020;40(5):503\u201316.","journal-title":"Cephalalgia"},{"key":"3600_CR53","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10194-012-0479-9","volume":"13","author":"S Ashina","year":"2012","unstructured":"Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, Reed ML, Buse DC. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012;13:615\u201324.","journal-title":"J Headache Pain"},{"issue":"24","key":"3600_CR54","doi-asserted-by":"publisher","first-page":"e2224","DOI":"10.1212\/WNL.0000000000008589","volume":"93","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Fanning KM, Buse DC, Martin VT, Hohaia LB, Adams AM, Reed ML, Goadsby PJ. Migraine progression in subgroups of migraine based on comorbidities: results of the CaMEO study. Neurology. 2019;93(24):e2224\u201336.","journal-title":"Neurology"},{"issue":"5","key":"3600_CR55","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1212\/WNL.0000000000004177","volume":"89","author":"AI Scher","year":"2017","unstructured":"Scher AI, Buse DC, Fanning KM, Kelly AM, Franznick DA, Adams AM, Lipton RB. Comorbid pain and migraine chronicity: the chronic migraine epidemiology and outcomes study. Neurology. 2017;89(5):461\u20138.","journal-title":"Neurology"},{"key":"3600_CR56","doi-asserted-by":"crossref","unstructured":"Hutchinson S, Lipton RB, Ailani J, Reed ML, Fanning KM, Adams AM, Buse DC. Characterization of acute prescription migraine medication use: results from the CaMEO study. In: Mayo Clinic Proceedings: 2020: Elsevier; 2020: 709\u2013718.","DOI":"10.1016\/j.mayocp.2019.11.025"},{"key":"3600_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01147-w","volume":"21","author":"P Pozo-Rosich","year":"2020","unstructured":"Pozo-Rosich P, Layos-Romero A, Martin-Delgado J, Pascual J, Bail\u00f3n C, Tentor A, Santiago A, Ignacio E, Torr\u00e9s A, Mira JJ. Low-value care practice in headache: a Spanish mixed methods research study. J Headache Pain. 2020;21:1\u20138.","journal-title":"J Headache Pain"},{"issue":"5","key":"3600_CR58","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40122-023-00538-6","volume":"12","author":"J Pascual","year":"2023","unstructured":"Pascual J, N\u00fa\u00f1ez M, Panni T, D\u00edaz-Cerezo S, Novick D, Ciudad A. Burden and Unmet needs in Migraine patients: results from the OVERCOME (Spain) Study. Pain Therapy. 2023;12(5):1209\u201320.","journal-title":"Pain Therapy"},{"issue":"8","key":"3600_CR59","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","volume":"48","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157\u201368.","journal-title":"Headache"},{"issue":"6","key":"3600_CR60","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.55.6.754","volume":"55","author":"SD Silberstein","year":"2000","unstructured":"Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754\u201362.","journal-title":"Neurology"},{"issue":"1","key":"3600_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"AH Society","year":"2019","unstructured":"Society AH. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache: J Head Face Pain. 2019;59(1):1\u201318.","journal-title":"Headache: J Head Face Pain"},{"key":"3600_CR62","doi-asserted-by":"publisher","first-page":"1231351","DOI":"10.3389\/fneur.2023.1231351","volume":"14","author":"K Yamato","year":"2023","unstructured":"Yamato K, Sano H, Hirata K, Nakayama T. Validation and comparison of the coding algorithms to identify people with migraine using Japanese claims data. Front Neurol. 2023;14:1231351.","journal-title":"Front Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03600-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03600-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03600-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T07:04:17Z","timestamp":1712041457000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03600-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3600"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03600-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"12 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted following the ethical principles of the Declaration of Helsinki and the local regulation, including privacy laws. The protocol was classified by the Agency of Medicines and Medical Devices (AEMPS) as an observational study and approved by the Ethics Committee of the Hospital Clinic of Barcelona (HCB\/2022\/1286). Informed consent to participate was waived by the same ethics committee that approved the study (Ethics Committee of Hospital Clinic of Barcelona).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JP has received in the last 3 years, honoraria as a consultant and speaker from Abbvie, Eli Lilly, Novartis, Pfizer and Teva Pharmaceuticals. PPR has received in the last 3 years, honoraria as a consultant and speaker from Abbvie, Amgen, Biohaven, Chiesi, Eli Lilly, Lundbeck, Medscape, Novartis, Pfizer and Teva Pharmaceuticals. Her research group has received research grants from Instituto Salud Carlos III, EraNet Neuron, AbbVie, Novartis, Teva Pharmaceuticals, AGAUR, FEDER RIS3CAT, and has received funding for clinical trials from Abbvie, Amgen, Biohaven, Eli Lilly, Lundbeck, Novartis, and Teva Pharmaceuticals. BA and CMA are Pfizer employees. AM and MC are IQVIA employees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}